Executive Summary
Ina Margaretha Rijnhout, MSc, is a Senior Partner at The Bracken Group who supports biotech and pharma companies with European clinical development and regulatory strategy, outsourcing strategy, and CRO selection. As a global and European Project Director, she managed large global clinical trials, leading multidisciplinary project teams, steering committees, and safety boards, and received multiple “best team of the year” awards.
Her business development experience ranges from helping start-ups raise capital, write business plans, set licensing strategy, and coordinate due diligence, to building long-term worldwide strategic alliances with top 10 pharma companies. She spent a decade leading strategic partnering and business development at PharmaNet, including as General Manager of its Benelux office, after heading new business development and clinical operations at Kendle. She has since led three biotechs as CEO, including GlycoTreat, which she founded to develop immunotherapy for food and other allergies.
A neuropharmacologist by training, with an MSc from Leiden University, she began her career in CNS research at MSD and GlaxoSmithKline. Her therapeutic expertise spans immunology, allergy, orphan, cardiovascular, neurology, psychiatry, and inflammatory diseases, across NCEs, gene therapy, cell therapy, medical devices, and biologicals.
Selected Client Projects
Areas of Expertise
Biotech Business Development
Capital raising, business plans, licensing strategy, and long-term strategic alliances with top 10 pharma companies.
European Clinical Development
Clinical development and regulatory strategy in Europe, from protocol development to steering committees and safety boards.
Outsourcing & CRO Selection
Clinical outsourcing strategy and CRO selection processes for pivotal clinical programs.
Licensing & Due Diligence
Coordinating CMC, preclinical, and clinical due diligence and identifying in-licensing opportunities at academia.
Orphan & Rare Disease Programs
Gene and cell therapy programs for orphan indications, from academic spin-offs to Phase III.
CRO Growth & M&A
Repositioning contract research organizations, restructuring business development, and identifying acquisition targets.
